Serum Levels of Matrix Metalloproteinase-1 in Brazilian Patients with Benign Prostatic Hyperplasia or Prostate Cancer

Table 1

Clinical data of individuals diagnosed with PCa or BPH.

	PCa (n = 20)	BPH (n = 176)
Age, years	66.0 ± 11.5	67.1 ± 10.2	0.637
BMI, kg/m^2	26.2 ± 3.8	25.7 ± 4.2	0.624
Glucose, mg/dl	104.3 ± 24.2	102.2 ± 31.7	0.772
HbA1c, %	5.8 ± 1.1	5.8 ± 1.3	0.988
Insulin, mU/mL	7.8 (3.2; 9.2)	5.7 (2.9; 10.0)	0.471^†
HOMA index	1.8 (0.8; 2.3)	1.4 (0.7; 2.5)	0.440^†
TGL, mg/dL	141.9 ± 42.1	156.7 ± 113.2	0.249
TC, mg/dL	204.2 ± 37.2	197.4 ± 48.2	0.538
VLDL cholesterol, mg/dL	28.4 ± 8.4	29.2 ± 16.4	0.727
LDL cholesterol, mg/dL	126.5 ± 35.2	114.6 ± 43.7	0.242
HDL cholesterol, mg/dL	49.4 ± 10.8	50.5 ± 13.0	0.710
SGOT, U/L	27.3 ± 11.7	27.6 ± 12.9	0.922
SGPT, U/L	25.6 ± 17.1	26.4 ± 15.4	0.815
GT, U/L	56.0 ± 42.6	49.0 ± 46.3	0.519
Creatinine, mg/dL	1.0 ± 0.2	1.1 ± 0.3	0.585
Total protein, g/dL	7.2 ± 0.5	7.4 ± 0.4	0.192
Albumin, g/dL	4.2 ± 0.4	4.4 ± 0.4	0.216
25-Hydroxy D3, nmol/L	29.4 ± 10.2	31.5 ± 13.1	0.486
CRP, mg/L	1.12 ± 0.77	1.11 ± 0.68	0.995
TSH, mU/L	1.8 (1.0; 3.2)	1.9 (1.2; 3.0)	0.931^†
Total PSA, ng/mL	21.8 (10.5; 34.6)	2.4 (1.1; 5.4)	<0.001^†
Free PSA, ng/mL	1.8 (0.5; 4.3)	0.4 (0.2; 0.9)	0.001^†
Free/total PSA ratio	8.0 (5.4; 16.1)	19.7 (13.0; 26.1)	<0.001^†

BMI: body mass index; BPH: benign prostatic hyperplasia; GT: gamma-glutamyl transferase; HbA1c: glycated hemoglobin type-A1c; HDL: high-density lipoprotein; HOMA: homeostasis model assessment; LDL: low-density lipoprotein; PCa: prostate cancer; PSA: prostate-specific antigen; SGOT: serum glutamic-oxaloacetic transaminase; SGPT: serum glutamic-pyruvic transaminase; TC: total cholesterol; TGL: triglycerides; TSH: thyroid stimulating hormone; VLDL: very low-density lipoprotein. Data are expressed within each group as mean ± standard deviation or median with interquartile intervals in brackets. values for comparison of differences are calculated using Student's t-test, exception is for the use of the Mann–Whitney test^† for nonparametric data.